Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
Public ClinicalTrials.gov record NCT02738775. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
Study identification
- NCT ID
- NCT02738775
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Interventions
- Ublituximab Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 26, 2016
- Primary completion
- Sep 26, 2017
- Completion
- Aug 12, 2018
- Last update posted
- Jul 14, 2021
2016 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Phoenix | Arizona | 85018 | — |
| TG Therapeutics Investigational Trial Site | Pasadena | California | 91105 | — |
| TG Therapeutics Investigational Trial Site | Torrance | California | 90502 | — |
| TG Therapeutics Investigational Trial Site | Aurora | Colorado | 80045 | — |
| TG Therapeutics Investigational Trial Site | Fort Collins | Colorado | 80528 | — |
| TG Therapeutics Investigational Trial Site | Lexington | Kentucky | 40509 | — |
| TG Therapeutics Investigational Trial Site | Teaneck | New Jersey | 07666 | — |
| TG Therapeutics Investigational Trial Site | Akron | Ohio | 44320 | — |
| TG Therapeutics Investigational Trial Site | Columbus | Ohio | 43201 | — |
| TG Therapeutics Investigational Trial Site | Knoxville | Tennessee | 37922 | — |
| TG Therapeutics Investigational Trial Site | Round Rock | Texas | 78681 | — |
| TG Therapeutics Investigational Trial Site | San Antonio | Texas | 78258 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02738775, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02738775 live on ClinicalTrials.gov.